{"count": 3, "results": [{"_id": "37143685", "pmid": 37143685, "pmcid": "PMC10151807", "title": "Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution", "journal": "Front Immunol", "authors": ["Garcia-Donas J", "Martínez-Urbistondo D", "Velázquez Kennedy K", "Villares P", "Barquin A", "Dominguez A", "Rodriguez-Moreno JF", "Caro E", "Suarez Del Villar R", "Nistal-Villan E", "Yagüe M", "Ortiz M", "Barba M", "Ruiz-Llorente S", "Quiralte M", "Zanin M", "Rodríguez C", "Navarro P", "Berraondo P", "Madurga R"], "date": "2023-04-18T00:00:00Z", "doi": "10.3389/fimmu.2023.1156603", "meta_date_publication": "2023", "meta_volume": "14", "meta_issue": "", "meta_pages": "1156603", "score": 50250.598, "text_hl": "We designed a randomized phase II clinical trial to determine whether the combination of @CHEMICAL_ruxolitinib @CHEMICAL_MESH:C540383 @@@ruxolitinib@@@ (5 mg twice a day for 7 days followed by 10 mg BID for 7 days) plus @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ (40 mg once a day for 14 days), could reduce the incidence of @<m>DISEASE_Respiratory_Insufficiency</m> @DISEASE_MESH:D012131 @@@respiratory insufficiency@@@ in @DISEASE_COVID_19 @DISEASE_MESH:D000086382 @@@COVID-19@@@. 48 cytokines were correlated with clinical outcome.", "citations": {"NLM": "Garcia-Donas J, Martínez-Urbistondo D, Velázquez Kennedy K, Villares P, Barquin A, Dominguez A, Rodriguez-Moreno JF, Caro E, Suarez Del Villar R, Nistal-Villan E, Yagüe M, Ortiz M, Barba M, Ruiz-Llorente S, Quiralte M, Zanin M, Rodríguez C, Navarro P, Berraondo P, Madurga R. Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution Front Immunol. 2023;14():1156603. PMID: 37143685", "BibTeX": "@article{37143685, title={Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution}, author={Garcia-Donas J and Martínez-Urbistondo D and Velázquez Kennedy K and Villares P and Barquin A and Dominguez A and Rodriguez-Moreno JF and Caro E and Suarez Del Villar R and Nistal-Villan E and Yagüe M and Ortiz M and Barba M and Ruiz-Llorente S and Quiralte M and Zanin M and Rodríguez C and Navarro P and Berraondo P and Madurga R}, journal={Front Immunol}, volume={14}, pages={1156603}}"}}, {"_id": "17257373", "pmid": 17257373, "title": "Simvastatin reduces ergosterol levels, inhibits growth and causes loss of mtDNA in Candida glabrata.", "journal": "FEMS Yeast Res", "authors": ["Westermeyer C", "Macreadie IG"], "date": "2007-05-01T00:00:00Z", "doi": "10.1111/j.1567-1364.2006.00194.x", "meta_date_publication": "2007 May", "meta_volume": "7", "meta_issue": "3", "meta_pages": "436-41", "score": 50050.97, "text_hl": "As @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@-treated cultures of @SPECIES_4932 @@@yeast@@@ were passaged, the frequencies of petite cells (@<m>DISEASE_Respiratory_Insufficiency</m> @DISEASE_MESH:D012131 @@@respiratory-deficient@@@ @SPECIES_4932 @@@yeast@@@ mutants with deletions in the mitochondrial genome) increased with time and with @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ concentration. ", "citations": {"NLM": "Westermeyer C, Macreadie IG. Simvastatin reduces ergosterol levels, inhibits growth and causes loss of mtDNA in Candida glabrata. FEMS Yeast Res. 2007 May;7(3):436-41. PMID: 17257373", "BibTeX": "@article{17257373, title={Simvastatin reduces ergosterol levels, inhibits growth and causes loss of mtDNA in Candida glabrata.}, author={Westermeyer C and Macreadie IG}, journal={FEMS Yeast Res}, volume={7}, number={3}, pages={436-41}}"}}, {"_id": "24516105", "pmid": 24516105, "title": "Simvastatin treatment attenuates increased respiratory variability and apnea/hypopnea index in rats with chronic heart failure.", "journal": "Hypertension", "authors": ["Haack KK", "Marcus NJ", "Del Rio R", "Zucker IH", "Schultz HD"], "date": "2014-05-01T00:00:00Z", "doi": "10.1161/HYPERTENSIONAHA.113.02535", "meta_date_publication": "2014 May", "meta_volume": "63", "meta_issue": "5", "meta_pages": "1041-9", "score": 50044.242, "text_hl": "Our findings demonstrate that the increased CBC sensitivity, @<m>DISEASE_Respiratory_Insufficiency</m> @DISEASE_MESH:D012131 @@@respiratory instability@@@, and @DISEASE_Arrhythmias_Cardiac @DISEASE_MESH:D001145 @@@cardiac arrhythmias@@@ observed in @DISEASE_Heart_Failure @DISEASE_MESH:D006333 @@@CHF@@@ are ameliorated by @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@statin@@@ treatment and suggest that statins may be an effective treatment for @DISEASE_Cheyne_Stokes_Respiration @DISEASE_MESH:D002639 @@@Cheyne-Stokes respiration@@@ and @DISEASE_Arrhythmias_Cardiac @DISEASE_MESH:D001145 @@@arrhythmias@@@ in @SPECIES_9606 @@@patient@@@ populations with high chemoreflex sensitivity. ", "citations": {"NLM": "Haack KK, Marcus NJ, Del Rio R, Zucker IH, Schultz HD. Simvastatin treatment attenuates increased respiratory variability and apnea/hypopnea index in rats with chronic heart failure. Hypertension. 2014 May;63(5):1041-9. PMID: 24516105", "BibTeX": "@article{24516105, title={Simvastatin treatment attenuates increased respiratory variability and apnea/hypopnea index in rats with chronic heart failure.}, author={Haack KK and Marcus NJ and Del Rio R and Zucker IH and Schultz HD}, journal={Hypertension}, volume={63}, number={5}, pages={1041-9}}"}}]}